Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
T.ONC
Alternate Symbol(s):
ONCY
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and...
adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(5345)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 24, 2024 12:04pm
RE:RE:RE:Biotech industry readies for " Pharma M&A Spree"
A growing emphasis on using synthetic control arms (SCA), which are derived from historical real-world evidence (RWE) using advanced statistical methods are becoming adopted by the
...more
(218)
•••
inthno
X
View Profile
View Bullboard History
Post by
inthno
on Nov 24, 2024 10:44am
Roche
MISSISSAUGA, ON – April 23, 2024 – Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on March 13, 2024, Health Canada issued marketing authorization for Tecentriq® SC
...more
(5345)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 23, 2024 4:32pm
RE:RE:RE:RE:CAR-T update
November 21, 2024 - “Unlike synthetic cancer drugs that we put into a patient, which have virtually all been developed in the last 100 years, the immune system has evolved since long before
...more
(5345)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 23, 2024 2:54pm
RE:RE:RE:CAR-T update
November 21, 2024 - Novartis is betting on direct cellular engineering through a collaboration with [oncolytic virus company] Vyriad, the companies announced Wednesday. “As an industry pioneer in the
...more
(207)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Nov 23, 2024 1:57pm
RE:RE:RE:RE:RE:My thanks , philosophical thoughts
If you read about car-t in general you will see that there are only a handful of fda approvals and the fda has a warning about using car-t. The industry is skiddish about jumping into this
...more
(5345)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 23, 2024 1:39pm
RE:RE:RE:Biotech industry readies for " Pharma M&A Spree"
November 19, 2024 - For “almost three years now” deal making has been a challenge across the life sciences industry, said Ed Saltman, senior strategic advisor at consultancy firm Lumanity, described
...more
(5345)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 23, 2024 11:10am
RE:RE:Biotech industry readies for " Pharma M&A Spree"
The recent push to plug patent-loss gaps by Big Pharma has left fewer late-stage biotechs available for Big Pharma to scoop up, so there are more deals around earlier-stage companies and assets. The
...more
(5345)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 23, 2024 10:49am
RE:RE:RE:RE:RE:How does Accelerated Approval work
With Replimmune leading the way on Accelerated Approval (AA) and the FDA granting Replimmune's intratumorally (IT) delivered OV therapy Breakthrough Therapy Designation (BTD), ONCY's
...more
(78)
•••
venture009
X
View Profile
View Bullboard History
Comment by
venture009
on Nov 23, 2024 10:36am
RE:RE:RE:RE:My thanks , philosophical thoughts
Quentin, I think March is too long a time frame. The economics of the US and global economies are in dire straits. It is going to get more and more difficult to get companies to part with their money
...more
(5345)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 22, 2024 6:42pm
RE:RE:RE:RE:How does Accelerated Approval work
As antibody-drug conjugates (ADCs) grow their importance in the oncology treatment space, efforts are underway to combine them with other agents, such as immune checkpoint inhibitors. That being said,
...more
(24)
•••
m00nsh0ts
X
View Profile
View Bullboard History
Comment by
m00nsh0ts
on Nov 22, 2024 6:02pm
RE:RE:RE:How does Accelerated Approval work
Merck also collaborating with PYXIS' ADC in the biologic area.
(5345)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 22, 2024 6:01pm
RE:RE:Biotech industry readies for " Pharma M&A Spree"
Furthermore, a Republican administration may be friendlier to large deals and may focus its drug pricing bite on PBMs rather than on pharma's deal-making activities.
(5345)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 22, 2024 5:55pm
RE:Biotech industry readies for " Pharma M&A Spree"
So what does that mean? The push to plug patent-loss gaps has left fewer late-stage biotechs available for Big Pharma to scoop up, so there are more deals around earlier-stage companies and assets
...more
(5345)
•••
Noteable
X
View Profile
View Bullboard History
Post by
Noteable
on Nov 22, 2024 5:26pm
Biotech industry readies for " Pharma M&A Spree"
November 16, 2024 - "Biotechnology and big pharma are noteworthy. Pharma needs biotech for new products, so M&A benefits both—securing revenue for pharma and providing premium buyouts for
...more
(5345)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 22, 2024 5:10pm
RE:RE:RE:RE:“Second mouse gets the cheese “
With Replimmune leading the way on Accelerated Approval (AA) and the FDA granting Replimmune's intratumorally (IT) delivered OV therapy Breakthrough Therapy Designation (BTD), ONCY's
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >